M. García-Bernal , R. Cilveti , M. Villa , J. Molina , R. Fernández-Delgado , I. Badell
{"title":"儿童急性淋巴细胞白血病和唐氏综合征:SHOP/ALL- 1999和2005协议的分析","authors":"M. García-Bernal , R. Cilveti , M. Villa , J. Molina , R. Fernández-Delgado , I. Badell","doi":"10.1016/S2171-9748(10)70011-8","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objective</h3><p><em>Down</em> syndrome bears a known predisposition to childhood leukemia. In regards to acute lymphoblastic leukemia (ALL), most international groups show poorer results when compared to non-Down patients.</p></div><div><h3>Patients and methods</h3><p>With this study we analyze the results obtained with Down syndrome patients and ALL younger than 18 years who were treated with SHOP (Spanish Pediatric Hematology Society) protocols for the past decade.</p></div><div><h3>Results</h3><p>Current data obtained from 1000 patients out of 32 centers confirm several aspects: those are related to acute leukemia showing clinical and biological low risk treats, thereof they may be categorized in low risk groups hence receive scheduled chemotherapy of moderate intensity. However, the number of infectious and toxic complications is greater than those for non-Down patients, therefore both overall survival (OS) and event free survival (EFS) are markedly affected.</p></div><div><h3>Conclusions</h3><p>The future aim is to optimize the knowledge on biological aspects of these leukemia, in order to determine those features to be acted upon to improve their outcome.</p></div>","PeriodicalId":100720,"journal":{"name":"International Medical Review on Down Syndrome","volume":"14 3","pages":"Pages 36-46"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2171-9748(10)70011-8","citationCount":"1","resultStr":"{\"title\":\"Acute lymphoblastic leukemia in children and Down syndrome: Analysis of SHOP/ALL-’99 and ‘05 Protocols\",\"authors\":\"M. García-Bernal , R. Cilveti , M. Villa , J. Molina , R. Fernández-Delgado , I. Badell\",\"doi\":\"10.1016/S2171-9748(10)70011-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction and objective</h3><p><em>Down</em> syndrome bears a known predisposition to childhood leukemia. In regards to acute lymphoblastic leukemia (ALL), most international groups show poorer results when compared to non-Down patients.</p></div><div><h3>Patients and methods</h3><p>With this study we analyze the results obtained with Down syndrome patients and ALL younger than 18 years who were treated with SHOP (Spanish Pediatric Hematology Society) protocols for the past decade.</p></div><div><h3>Results</h3><p>Current data obtained from 1000 patients out of 32 centers confirm several aspects: those are related to acute leukemia showing clinical and biological low risk treats, thereof they may be categorized in low risk groups hence receive scheduled chemotherapy of moderate intensity. However, the number of infectious and toxic complications is greater than those for non-Down patients, therefore both overall survival (OS) and event free survival (EFS) are markedly affected.</p></div><div><h3>Conclusions</h3><p>The future aim is to optimize the knowledge on biological aspects of these leukemia, in order to determine those features to be acted upon to improve their outcome.</p></div>\",\"PeriodicalId\":100720,\"journal\":{\"name\":\"International Medical Review on Down Syndrome\",\"volume\":\"14 3\",\"pages\":\"Pages 36-46\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S2171-9748(10)70011-8\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Medical Review on Down Syndrome\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2171974810700118\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Medical Review on Down Syndrome","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2171974810700118","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Acute lymphoblastic leukemia in children and Down syndrome: Analysis of SHOP/ALL-’99 and ‘05 Protocols
Introduction and objective
Down syndrome bears a known predisposition to childhood leukemia. In regards to acute lymphoblastic leukemia (ALL), most international groups show poorer results when compared to non-Down patients.
Patients and methods
With this study we analyze the results obtained with Down syndrome patients and ALL younger than 18 years who were treated with SHOP (Spanish Pediatric Hematology Society) protocols for the past decade.
Results
Current data obtained from 1000 patients out of 32 centers confirm several aspects: those are related to acute leukemia showing clinical and biological low risk treats, thereof they may be categorized in low risk groups hence receive scheduled chemotherapy of moderate intensity. However, the number of infectious and toxic complications is greater than those for non-Down patients, therefore both overall survival (OS) and event free survival (EFS) are markedly affected.
Conclusions
The future aim is to optimize the knowledge on biological aspects of these leukemia, in order to determine those features to be acted upon to improve their outcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
